TSOI

Therapeutic Solutions International, Inc.

OTC Markets OTCPKUSDEQUITY DELAYED

0.00

■ 0.00 (0.00%)

MARKET · —

Price

Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw

Open

—

Prev close

0.00

Day high

0.00

Day low

0.00

Volume

262.50K

Market cap

—

P/E (TTM)

—

52W range

0.00 – 0.00

Trailing performance

Price return · vs SPY

Returnvs SPY

0.00% +1.4%

0.00% -3.7%

0.00% -3.1%

0.00% -11.1%

YTD

0.00% -12.3%

0.00% -20.0%

-90.91% -165.1%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Free account

3 more panels on TSOI open with an account.

Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.

Create free account Sign in

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Financial statements

As reported · 3 years

Blank means not reported, not zero

Line item	2023	2022	2021	YoY
Total revenue	$98.99K	$206.77K	$145.96K	-52.1%
Operating revenue	$98.99K	$206.77K	$145.96K	-52.1%
Cost of revenue	$36.77K	$79.44K	$42.54K	-53.7%
Gross profit	$62.23K	$127.33K	$103.41K	-51.1%
Research & development	$560.65K	$1.45M	$794.75K	-61.4%
Selling, general & admin	$1.49M	$1.95M	$1.61M	-23.9%
Total operating expense	$2.05M	$3.41M	$2.41M	-39.9%
Operating income	-$1.99M	-$3.28M	-$2.30M	+39.4%
Net interest income	-$423.26K	-$646.09K	-$611.79K	+34.5%
Pre-tax income	-$2.22M	-$3.88M	-$2.96M	+42.7%
Tax provision	$2.25K	$1.60K	$800	+40.6%
Net income	-$2.17M	-$3.81M	-$2.96M	+43.1%
Net income to common	-$2.17M	-$3.81M	-$2.96M	+43.1%
Basic EPS	-0.00	-0.00	-0.00	+54.6%
Diluted EPS	-0.00	-0.00	-0.00	+54.6%
EBIT	-$1.80M	-$3.23M	-$2.35M	+44.3%
EBITDA	-$1.49M	-$2.99M	-$2.33M	+50.2%
Basic shares	3.17B	2.53B	2.26B	+25.3%
Diluted shares	3.17B	2.53B	2.26B	+25.3%

Line item

2023

2022

2021

YoY

Total revenue

$98.99K

$206.77K

$145.96K

-52.1%

Operating revenue

$98.99K

$206.77K

$145.96K

-52.1%

Cost of revenue

$36.77K

$79.44K

$42.54K

-53.7%

Gross profit

$62.23K

$127.33K

$103.41K

-51.1%

Research & development

$560.65K

$1.45M

$794.75K

-61.4%

Selling, general & admin

$1.49M

$1.95M

$1.61M

-23.9%

Total operating expense

$2.05M

$3.41M

$2.41M

-39.9%

Operating income

-$1.99M

-$3.28M

-$2.30M

+39.4%

Net interest income

-$423.26K

-$646.09K

-$611.79K

+34.5%

Pre-tax income

-$2.22M

-$3.88M

-$2.96M

+42.7%

Tax provision

$2.25K

$1.60K

$800

+40.6%

Net income

-$2.17M

-$3.81M

-$2.96M

+43.1%

Net income to common

-$2.17M

-$3.81M

-$2.96M

+43.1%

Basic EPS

-0.00

+54.6%

Diluted EPS

-0.00

+54.6%

EBIT

-$1.80M

-$3.23M

-$2.35M

+44.3%

EBITDA

-$1.49M

-$2.99M

-$2.33M

+50.2%

Basic shares

3.17B

2.53B

2.26B

+25.3%

Diluted shares

3.17B

2.53B

2.26B

+25.3%

Line item	2023	2022	2021	YoY
Cash & equivalents	$27.82K	$18.43K	$94.04K	+50.9%
Cash & short-term investments	$27.82K	$18.43K	$94.04K	+50.9%
Accounts receivable	$19.20K	$25.40K	$16.61K	-24.4%
Inventory	$22.57K	$42.43K	$39.82K	-46.8%
Total current assets	$85.91K	$309.62K	$1.12M	-72.3%
Property, plant & equipment	$499.91K	$281.69K	$318.21K	+77.5%
Goodwill & intangibles	$2.70M	$3.00M	$129.07K	-10.0%
Total assets	$3.29M	$3.61M	$1.72M	-8.7%
Total current liabilities	$1.90M	$2.21M	$2.50M	-14.1%
Current debt	$757.00K	$1.06M	$1.05M	-28.5%
Long-term debt	$5.51K	$10.51K	$15.53K	-47.5%
Total debt	$888.06K	$1.08M	$1.10M	-17.6%
Total liabilities	$2.01M	$2.22M	$2.52M	-9.5%
Retained earnings	-$20.33M	-$18.16M	-$13.99M	-12.0%
Shareholder equity	$1.13M	$1.22M	-$804.98K	-7.9%
Working capital	-$1.81M	-$1.90M	-$1.38M	+4.6%
Net tangible assets	-$1.58M	-$1.78M	-$934.06K	+11.5%
Shares issued	3.80B	2.62B	2.31B	+45.3%

Line item

2023

2022

2021

YoY

Cash & equivalents

$27.82K

$18.43K

$94.04K

+50.9%

Cash & short-term investments

$27.82K

$18.43K

$94.04K

+50.9%

Accounts receivable

$19.20K

$25.40K

$16.61K

-24.4%

Inventory

$22.57K

$42.43K

$39.82K

-46.8%

Total current assets

$85.91K

$309.62K

$1.12M

-72.3%

Property, plant & equipment

$499.91K

$281.69K

$318.21K

+77.5%

Goodwill & intangibles

$2.70M

$3.00M

$129.07K

-10.0%

Total assets

$3.29M

$3.61M

$1.72M

-8.7%

Total current liabilities

$1.90M

$2.21M

$2.50M

-14.1%

Current debt

$757.00K

$1.06M

$1.05M

-28.5%

Long-term debt

$5.51K

$10.51K

$15.53K

-47.5%

Total debt

$888.06K

$1.08M

$1.10M

-17.6%

Total liabilities

$2.01M

$2.22M

$2.52M

-9.5%

Retained earnings

-$20.33M

-$18.16M

-$13.99M

-12.0%

Shareholder equity

$1.13M

$1.22M

-$804.98K

-7.9%

Working capital

-$1.81M

-$1.90M

-$1.38M

+4.6%

Net tangible assets

-$1.58M

-$1.78M

-$934.06K

+11.5%

Shares issued

3.80B

2.62B

2.31B

+45.3%

Line item	2023	2022	2021	YoY
Net income	-$2.22M	-$3.88M	-$2.96M	+42.6%
Depreciation & amortisation	$311.78K	$244.63K	$18.07K	+27.4%
Stock-based compensation	$395.55K	$1.64M	$1.34M	-75.9%
Change in working capital	$264.64K	$518.42K	$299.30K	-49.0%
Operating cash flow	-$1.06M	-$1.04M	-$718.92K	-1.7%
Capital expenditure	-$16.16K	—	-$260.56K	—
Investing cash flow	-$24.00K	$0	-$256.55K	—
Financing cash flow	$1.08M	$943.09K	$817.38K	+14.3%
Free cash flow	-$1.07M	-$1.04M	-$979.49K	-3.2%
End cash position	$27.82K	$29.44K	$104.26K	-5.5%

Line item

2023

2022

2021

YoY

Net income

-$2.22M

-$3.88M

-$2.96M

+42.6%

Depreciation & amortisation

$311.78K

$244.63K

$18.07K

+27.4%

Stock-based compensation

$395.55K

$1.64M

$1.34M

-75.9%

Change in working capital

$264.64K

$518.42K

$299.30K

-49.0%

Operating cash flow

-$1.06M

-$1.04M

-$718.92K

-1.7%

Capital expenditure

-$16.16K

—

-$260.56K

—

Investing cash flow

-$24.00K

-$256.55K

—

Financing cash flow

$1.08M

$943.09K

$817.38K

+14.3%

Free cash flow

-$1.07M

-$1.04M

-$979.49K

-3.2%

End cash position

$27.82K

$29.44K

$104.26K

-5.5%

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

0.00

+0.00% from price

SMA 20

0.00

0.00% from price

SMA 50

0.00

0.00% from price

SMA 100

0.00

+0.00% from price

SMA 200

0.00

0.00% from price

EMA 12

0.00

+0.00% from price

EMA 26

0.00

+0.00% from price

EMA 50

0.00

-0.00% from price

RSI (14)

46.0

Neutral

MACD (12,26,9)

-0.00

Hist 0.00

ATR (14)

0.00

—

Realised vol 30D

0.0%

Annualised

Bollinger upper

0.00

20, 2σ

Bollinger lower

0.00

20, 2σ

50 / 200 cross

Death

0.00 vs 0.00

Trend bias

Below 200

0.00%

Options chain

Account required

ExpirySpot 0.00

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.00

Less volatile than market

Correlation to SPY

—

Realised vol 30D

0.0%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

0.0%

Peak to trough

Max drawdown 5Y

-99.9%

Peak to trough

ATR 14

0.00

Average true range

Beta (reported)

—

5Y monthly, from filing

Headlines

TSOI · links out to the publisher

Orthofix Medical Inc. Q2 2026 Earnings Call Summary Moby · 17d ago Orthofix Medical (OFIX) Among the Best Small-Cap Growth Stocks To Buy Now Insider Monkey · 51d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.